CCNA2 and ovarian carcinoma: In addition, CEP is also a potential anti-cancer drug for ovarian cancer by markedly increasing p21 expression and decreasing cyclins A and D levels in human ovarian cancer CaOV-3 and OVCAR3 cells [787].